Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 3/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | IAPP | P10997 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27018396 | 0.88 | LTB4R (0.43) | LTB4RLTB4R2PPARAHDAC1HDAC6 | |
| SCHEMBL26224350 | 0.87 | LTB4R (0.41) | LTB4RLTB4R2PPARAHDAC1HDAC6 | |
| SCHEMBL26229265 | 0.79 | PPARA (0.38) | LTB4RLTB4R2PPARAHDAC1HDAC6 | |
| SCHEMBL26224374 | 0.77 | KDM4E (0.40) | — | |
| SCHEMBL26224379 | 0.76 | CYP1A2 (0.41) | PPARAHDAC1HDAC6IAPPPPARG | |
| SCHEMBL26224339 | 0.75 | PPARA (0.55) | PPARAHDAC1HDAC6PPARG | |
| SCHEMBL25122722 | 0.74 | LTB4R (0.42) | LTB4RLTB4R2PPARAHDAC1HDAC6 | |
| SCHEMBL27018426 | 0.74 | CYP4F2 (0.47) | LTB4RLTB4R2PPARAHDAC1HDAC6 | |
| SCHEMBL26224372 | 0.73 | TSHR (0.38) | PPARAPPARG | |
| SCHEMBL23845280 | 0.73 | LTB4R (0.43) | LTB4RLTB4R2PPARAHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | LTB4R 2439/4885LTB4R2 2981/4885PPARA 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.